Kezar Life Sciences (KZR) Cash from Operations (2021 - 2025)
Historic Cash from Operations for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to -$9.8 million.
- Kezar Life Sciences' Cash from Operations rose 4380.93% to -$9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$56.6 million, marking a year-over-year increase of 2583.18%. This contributed to the annual value of -$74.2 million for FY2024, which is 910.4% up from last year.
- Kezar Life Sciences' Cash from Operations amounted to -$9.8 million in Q3 2025, which was up 4380.93% from -$12.8 million recorded in Q2 2025.
- Over the past 5 years, Kezar Life Sciences' Cash from Operations peaked at -$8.4 million during Q1 2021, and registered a low of -$22.9 million during Q1 2024.
- Over the past 5 years, Kezar Life Sciences' median Cash from Operations value was -$16.4 million (recorded in 2022), while the average stood at -$15.6 million.
- As far as peak fluctuations go, Kezar Life Sciences' Cash from Operations crashed by 6435.6% in 2022, and later skyrocketed by 4380.93% in 2025.
- Over the past 5 years, Kezar Life Sciences' Cash from Operations (Quarter) stood at -$11.1 million in 2021, then plummeted by 43.34% to -$15.9 million in 2022, then fell by 19.5% to -$19.0 million in 2023, then grew by 11.35% to -$16.8 million in 2024, then surged by 41.58% to -$9.8 million in 2025.
- Its Cash from Operations stands at -$9.8 million for Q3 2025, versus -$12.8 million for Q2 2025 and -$17.2 million for Q1 2025.